The core of Edden’s argument rests on a deceptively simple observation about the anatomy of clinical reasoning. Documentation is often treated as clerical work, a downstream record of decisions already made. But there is a specific moment in the writing of a clinical note — the drafting of the differential diagnosis and plan — where something cognitively profound occurs. At that moment, the clinician compiles facts gathered during the encounter, prioritizes their significance, and translates a sprawling, ambiguous clinical picture into a coherent judgment and a plan of action. It is a brief inward interval in which external inputs recede and the complexity of the case is condensed into a clinical trajectory. The note, in other words, is not merely a record of what the clinician decided. It is the very site where the clinician decides what the case is becoming.

This distinction matters because of a fundamental truth about diagnostic medicine that cognitive researchers have documented for decades: diagnoses are rarely reached unless they are first imagined. Clinical reasoning depends not only on the information available but on whether a diagnostic possibility is actively entertained at all. When a high-stakes possibility never enters a clinician’s mind, relevant findings may remain fragmented or be quietly absorbed into more familiar explanations. Conversely, once a serious possibility is consciously considered, the clinical task changes character — the obligation shifts from merely noting it to evaluating it and, when appropriate, actively excluding it. Diagnostic safety, Edden argues, begins before confirmation, at the moment a potential trajectory becomes visible enough to demand action. Anything that influences what becomes visible at that moment therefore wields enormous influence over patient outcomes.

Enter generative AI. As these systems move from passive transcription toward active synthesis — suggesting, organizing, and prioritizing diagnostic possibilities within the medical record — they stop being neutral scribes and become participants in the formation of clinical meaning. The systems can shape which trajectories are constructed, which are emphasized, and which are prematurely dismissed. This influence cuts in both directions. On one hand, it could genuinely improve care by expanding the range of possibilities a clinician considers, particularly during complex presentations, under time pressure, or when information is fragmented across multiple visits and specialists. On the other hand, it introduces familiar risks that psychology has catalogued extensively: anchoring on initial suggestions, selective emphasis that privileges one explanation over others, automation bias in which humans defer to machine output, and premature closure in which thinking stops too soon.

To make the stakes concrete, Edden reaches for an analogy that will resonate with anyone who has ever driven a car: road navigation. Digital navigation systems such as GPS did not merely reduce errors and improve travel efficiency. Research shows they changed how routes are perceived, evaluated, and chosen. Drivers remain nominally responsible for the trip, yet the path is increasingly shaped by an external system that selects options, estimates delays, and makes some alternatives visible while rendering others effectively invisible. Over time, studies of GPS use have suggested effects on spatial knowledge itself — the internal map that once guided navigation atrophies when an external system does the choosing. The driver still drives, but the structure of the decision has been reorganized around the tool.

A similar transition, Edden suggests, may now be emerging in clinical reasoning. As AI enters the stage at which diagnostic and therapeutic direction is formed — not after decisions are made, but while they are taking shape — the locus of navigation may shift from internally constructed diagnostic pathways toward system-influenced trajectories. This does not necessarily mean a loss of clinical judgment, he is careful to note, but rather a change in its structure. Possibilities may be surfaced differently, weighed differently, and acted upon differently when an external system helps shape the path forward. A physician may still approve, edit, or reject the AI’s framing, but the framing itself — the set of options laid on the table — is increasingly co-authored by the machine.

The practical implications of this shift reach well beyond the quality of the notes in a patient’s chart. They touch on how clinical judgment is formed, how responsibility is exercised, and how medical knowledge is enacted in daily practice. The critical question, Edden argues, is not simply whether generative AI improves accuracy on benchmarks, but how it reshapes the moment in which clinical direction is determined. A polished, coherent, AI-drafted note might look excellent on the page while still narrowing attention — making one explanation appear natural and complete while leaving alternatives underdeveloped or absent entirely. Accuracy of prose is not the same as accuracy of reasoning, and the two can diverge in ways that are invisible to a time-pressed reader.

For individual clinicians, the article’s prescription is a form of deliberate cognitive vigilance. AI-assisted documentation should be treated as part of the reasoning process, not as a neutral clerical layer sitting underneath it. Engaging with these systems requires awareness, reflection, and at times deliberate override. Edden proposes that clinicians ask not only whether an AI-generated note is accurate, but whether its structure, emphasis, and omissions are shaping the diagnostic path itself. Does the drafted differential include the diagnosis that must not be missed? Has the system’s ordering of possibilities subtly reordered the clinician’s own priorities? When this kind of influence is recognized, it can be navigated and corrected; when it remains hidden, it may redirect care without anyone noticing that a redirect has occurred.

For health systems and institutions, the implications are equally demanding. Edden argues that evaluation of AI documentation tools must extend beyond the metrics that dominate current procurement conversations — note quality scores, completion times, and clinician satisfaction surveys. Governance should examine how these tools influence diagnostic framing, escalation decisions, and closure in everyday work. Training, too, needs to evolve: clinicians should be prepared to interrogate AI-generated framing, not merely edit AI-generated prose. That is a fundamentally different skill, one that treats the machine’s output as a hypothesis to be tested rather than a draft to be polished. Institutions that deploy these systems without examining their reasoning-level effects, the article implies, may be optimizing documentation while silently perturbing diagnosis.

The deeper message of the viewpoint is ultimately philosophical. Clinical AI is changing not only what tools clinicians use but how they think — and the change is arriving through the back door of documentation rather than the front door of decision support. Documentation, as Edden puts it, captures events after they have taken form; navigation concerns direction before consequences fully emerge. As AI systems embed themselves in the cognitive workflow of care, clinicians and institutions must recognize that the medical record is no longer only a record of reasoning. It is increasingly a site where reasoning itself is shaped — and the moment to notice that transformation is now, while the clinicians and the algorithms are still learning from each other.

Subject of Research: The influence of generative artificial intelligence documentation tools on clinical reasoning and diagnostic decision-making

Article Title: From Documentation to Navigation: How Generative Artificial Intelligence Influences Clinical Reasoning

Article References: Edden, Y. (2026). From Documentation to Navigation: How Generative Artificial Intelligence Influences Clinical Reasoning. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10836-2

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10836-2

Keywords: generative AI, clinical reasoning, medical documentation, diagnostic error, differential diagnosis, automation bias, anchoring, premature closure, GPS navigation analogy, clinical decision-making, health system governance, Journal of General Internal Medicine

In a groundbreaking study involving collaboration among Penn State College of Medicine, Brown University, and Seton Hall University School of Law, researchers investigated how mock jurors judge the liability of radiologists in hypothetical malpractice scenarios where AI flagged abnormalities in brain scans that the radiologist failed to identify. The study revealed a profound impact of workflow design on legal perceptions: jurors were nearly 50% more inclined to side with plaintiffs when the radiologist reviewed the scan only once after AI alert, compared to when the radiologist examined the images twice—once prior to and once after AI input.

This finding indicates that jurors attribute greater negligence to radiologists who appear to rely passively on AI outputs, rather than actively engaging with both their expertise and AI assistance through multiple evaluations. The dual-review workflow, entailing an initial radiologist assessment followed by AI feedback and a subsequent review, seems to convey a more diligent and thorough diagnostic process. Consequently, the legal threshold for meeting the “duty of care” appears closely tied to evidence of such methodical interactions between human clinicians and AI.

The study’s experimental design centered on a fictitious but plausible medical malpractice suit. Participants, recruited to act as lay jurors, examined one of two carefully crafted scenarios simulating the detection of a brain hemorrhage via computerized tomography (CT). In both, AI correctly identified an abnormality, but the radiologist’s conclusion denied its presence. Differences in juror decision-making starkly contrasted the workflows, underscoring the judicial system’s nuanced interpretation of human-AI collaboration in clinical practice.

Importantly, about 75% of jurors determined a breach of duty when the radiologist enlisted AI feedback but reviewed the scan only once afterward. This figure dropped to 53% when the radiologist performed two separate reads bracketing the AI alert. These statistics emphasize that workflow adjustments that foster active, iterative engagement with AI findings may mitigate legal exposure, a crucial insight for healthcare providers contemplating the adoption of AI tools in diagnostics.

Yet, prudence is warranted. The researchers caution that asking radiologists to reinterpret scans multiple times may introduce operational complexities and increased costs in clinical settings. Moreover, cognitive biases further complicate the landscape. Radiologists may feel pressured to conform to AI’s conclusions for fear of legal repercussions if they dissent and are proven wrong. Such dynamics could paradoxically compromise diagnostic rigor and exacerbate patient anxiety through excess follow-up testing and healthcare expenditure.

This phenomenon highlights a critical tension at the intersection of AI implementation and medical liability: balancing the need for thoroughness and accountability against resource constraints and human factors. Legal experts underscore that these concerns bear heavily on procurement decisions for AI technologies, clinical protocol development, and strategies around litigation or settlement in cases of alleged malpractice.

The researchers purposely focused on radiology, given its advanced state of AI integration compared to other specialties. Radiology’s heavy reliance on imaging data and algorithmic interpretations provides a fertile ground for studying how human and machine cognition intertwine in high-stakes decision-making. Still, the implications likely extend across healthcare disciplines as AI becomes more entrenched in diagnostics and treatment paradigms.

Beyond measuring liability perceptions, prior work by this team revealed that jurors are less inclined to hold radiologists accountable when their diagnoses align with AI outputs, whereas disagreement with AI seemingly increases perceived culpability. Disclosure of AI error rates to juries also modulates these judgments, underscoring that transparency around AI capabilities and limitations is critical in fostering informed legal assessments.

Moreover, other studies illustrate that AI not only affects post-hoc liability views but also shapes real-time clinical decisions. Physicians confronted with AI recommendations often adjust treatment plans, reflecting how decision-making authority becomes shared or contested between human experts and algorithmic systems. This evolving dynamic demands continuous scholarly attention as technology and societal norms co-evolve.

Corresponding author Michael Bernstein of Brown University notes that public and professional attitudes toward AI’s diagnostic role—and consequent legal ramifications—are swiftly changing. Such shifts necessitate agile policy frameworks and adaptive clinical workflows that integrate human factors principles to optimize outcomes and minimize unintended consequences.

The broader challenge lies in reconciling AI’s promise to enhance diagnostic accuracy and patient safety with the multifaceted risks posed by legal uncertainty, workflow disruption, and cognitive biases. As this research compellingly demonstrates, successful human-AI integration must address not only technological efficacy but also the social, legal, and psychological dimensions that govern stakeholder acceptance and trust.

Future investigations will likely explore how different organizational policies, educational initiatives, and legal standards can harmonize with emerging AI capabilities to foster a healthcare environment where technology acts as a reliable, transparent ally rather than a source of liability anxiety or defensive practice patterns. The evolving jurisprudence around AI in medicine will be pivotal in shaping an ethical, effective, and equitable future for patient care.

As AI continues its inexorable advance through medicine, understanding the nuanced relationships among clinical workflows, legal accountability, and human judgment will become ever more crucial. This study stands as a timely beacon, illuminating how thoughtful integration strategies, grounded in empirical evidence, can help navigate the complex terrain at the confluence of innovation and responsibility.

Subject of Research: People
Article Title: The radiologist–AI workflow and the risk of medical malpractice claims
News Publication Date: 10-Mar-2026
Web References: DOI 10.1038/s44360-026-00085-2
Keywords: Artificial intelligence, Health care, Health care costs, Medical economics, Health care delivery, Health care policy, Litigation, Legal system, Radiology

The core of the discussion revolved around the accelerating integration of AI-driven tools within oncology practices and the critical juncture at which the medical community finds itself. Dr. Travis Osterman, an eminent figure in cancer clinical informatics at Vanderbilt-Ingram Cancer Center and a key voice in the NCCN Digital Oncology Forum, eloquently positioned this moment as an inflection point. According to him, the timely establishment of regulatory frameworks and thoughtfully crafted policy guardrails will be decisive in ensuring that AI enhances rather than disrupts the clinical workflow, patient safety, and care efficacy. Osterman underscored that the decisions made today will set the trajectory for AI’s sustainable incorporation into oncological care paradigms for years to come.

Despite the cautious optimism permeating the summit, leading authorities emphasized a pragmatic approach to adoption. William Walders, Executive Vice President and Chief Digital and Information Officer at The Joint Commission, articulated the present reality: AI technologies are neither speculative nor distant prospects but active components in contemporary oncology. Tools powered by machine learning are already instrumental in early disease detection, guiding treatment personalization, and alleviating administrative burdens on clinicians. Walders identified a critical necessity—designing safeguards and trust-building mechanisms that protect patients and reinforce the humanistic core of oncological care, ensuring that AI functions as a complementary force rather than a replacement for human judgment.

The rapid pace of AI model development was a recurring theme, with speakers drawing parallels to revolutionary milestones in medical history. The shift from paper-based to electronic medical records (EMRs) was invoked as a historical analogue, exemplifying how profound technological shifts can both disrupt and enhance clinical workflows. Summit participants conveyed palpable excitement for AI’s promise—not only in streamlining clinical operations but also in addressing the pressing crisis of workforce shortages in oncology and accelerating the pipeline of novel therapeutic discoveries.

Dr. Jorge Reis-Filho, Chief AI and Data Scientist at AstraZeneca’s Oncology R&D division, emphasized the unprecedented opportunities enabled by recent advances in multimodal foundation models and agentic AI. Such models, capable of synthesizing diverse data streams—from genomic sequences to imaging and clinical records—hold the potential to revolutionize biomarker discovery and refine the biological understanding of malignancies. This integrative, multi-dimensional data analysis could markedly improve precision oncology, tailoring interventions to the unique molecular signatures of individual tumors and enhancing therapeutic outcomes.

Clinical trial innovation also emerged as a pivotal area poised for AI-driven disruption. According to Dr. Danielle Bitterman of Mass General Brigham, AI’s ability to dismantle geographical and logistical barriers could democratize clinical trial access, extending life-saving investigational therapies to patients irrespective of their physical proximity to research centers. Moreover, the automation and simplification of complex trial protocols, powered by AI decision-support systems, promise to reduce trial inefficiencies and improve data integrity, thus hastening the translational journey from bench to bedside.

The interdisciplinary nature of AI’s integration into oncology was a key focal point, with calls for strengthened collaborations between oncologists and computer scientists. This partnership is anticipated to catalyze advances by ensuring that AI tools are pragmatically aligned with clinical realities and patient-centered objectives. Such synergy is viewed as indispensable for overcoming technical hurdles and ethical concerns alike, facilitating co-design processes that marry computational innovation with frontline clinical insight.

MIT’s Regina Barzilay, a prominent AI and health engineering professor, voiced a note of urgency amid the excitement. She warned that the actual uptake of AI-driven diagnostics and therapeutics lags behind technological capabilities. Barzilay advocated explicitly for the development and implementation of clinical guidelines that would mandate or incentivize the use of validated AI tools, thus accelerating their translation into routine patient care and overcoming institutional inertia and skepticism.

While the enthusiasm for AI’s potential was palpable, participants did not shy away from less optimistic perspectives. Significant challenges remain in implementing quality control and accreditation processes for AI algorithms in a manner that is rigorous yet not prohibitively burdensome. Furthermore, consensus on appropriate governmental and regulatory oversight remains elusive, creating a landscape of uncertainty that may stifle innovation or, contrarily, risk accelerating adoption without adequate safeguards.

The summit also highlighted the importance of fostering collaboration between medical practitioners and technology developers to optimize AI deployment. There is widespread recognition that neither domain can succeed in isolation. Successful AI applications hinge on intricate, real-world datasets and clinical insight, balanced with robust algorithmic validation and transparent, explainable models that clinicians trust and understand.

Interoperability was another pressing topic, as AI’s benefits can be undermined without seamless integration across heterogeneous healthcare IT systems. Fragmented platforms, inconsistent data standards, and siloed information flow impede AI’s ability to provide comprehensive decision support, reinforcing the need for unified frameworks and data-sharing protocols.

Equity considerations received significant attention. Summit attendees expressed concern that AI deployment risks exacerbating existing disparities in cancer care, particularly among under-resourced populations. Ensuing technology gaps within healthcare systems and patient communities could widen, unless deliberate strategies are undertaken to ensure universal access, culturally competent design, and bias mitigation within AI algorithms.

Moreover, the essential human element in oncology care—the nuanced, empathetic clinician-patient relationship—must be preserved. AI systems, while powerful, are vulnerable to errors, misinterpretations, and intrinsic biases inherent in training datasets. Sustaining the human touch remains paramount, and AI must be positioned as an augmentative tool that supports, rather than supplants, clinical expertise and judgment.

Allen Rush, co-founder of the Jacqueline Rush Lynch Syndrome Cancer Foundation, encapsulated the summit’s consensus by emphasizing the need to look beyond medical silos. He advocated for partnerships leveraging expertise from non-medical industries, particularly those with deep experience in AI and adaptive systems. By “teaming up” to co-develop and fine-tune AI applications, the oncology community could unlock unprecedented possibilities in early cancer detection and personalized treatment.

The Policy Summit is part of a broader NCCN effort to promulgate dialogue and education around AI’s role in oncology, with related sessions conducted during the NCCN 2025 Annual Conference. Upcoming events, such as the December 2025 Patient Advocacy Summit focusing on veterans and first responders, continue this momentum.

As AI continues its rapid evolution, the oncology community stands at a crossroads. The coming years will be critical in shaping a future where machine intelligence complements human compassion, improving cancer outcomes through precision, efficiency, and equity. The commitment demonstrated at this summit signals a readiness to navigate technical challenges and ethical considerations alike, ensuring that AI’s integration into cancer care is both responsible and revolutionary.

Subject of Research: Artificial Intelligence in Cancer Care and Oncology Policy

Article Title: NCCN Oncology Policy Summit Explores Cutting-Edge AI Innovations Set to Transform Cancer Care

News Publication Date: September 9, 2025

Web References:
https://www.nccn.org/business-policy/policy-and-advocacy-program/oncology-policy-summits
https://www.nccn.org/conference

Image Credits: NCCN

Keywords: Artificial intelligence, Generative AI, Machine learning, Electronic medical records, Medical technology, Cancer policy, Cancer treatments, Oncology, Cancer, Cancer screening